Japan, June 10 -- NUMAB THERAPEUTICS AG has got intellectual property rights for 'ANTIBODIES TARGETING PDL1 AND METHODS OF USE THEREOF.' Other related details are as follows:
Application Number: JP,2025-035270
Category (FI): C07K19/00,C12N1/15,C12N1/19,A61K39/395@U,A61K39/395@T,C12N15/62@Z,A61P35/00,C12N1/21,C12N5/10,C07K16/28,C07K16/46,C12N15/13,C12P21/08,A61K39/395@N
Stage: Grant (IP right granted following substantive examination.)
Filing Date: March 6, 2025
Publication Date: July 8, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
